Provided is a recombinant Ab clone G1 that exhibits a characteristic TCR-like binding specificity, yet, unlike TCRs, it did so with a high affinity in the nanomolar range. The TCR-like Ab can recognize the native MHC-peptide complex expressed on the surface of APCs, and on peptide-pulsed or native melanoma cells. Moreover, when fused to a very potent cytotoxic effector molecule in the format of a truncated bacterial toxin, it was able to specifically kill APCs in a peptide-dependent manner.
Figure 1 Binding characteristics of the TCR-like G1 scFv.
Titration ELISA of purified soluble G1 scFv.
Denkberg, G., Lev, A., Eisenbach, L., Benhar, I., & Reiter, Y. (2003). Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. Journal of immunology (Baltimore, Md. : 1950), 171(5), 2197–2207.
Figure 2 Binding of G1 scFv to peptide-pulsed APCs and melanoma cells.
The gp100-derived peptide and control peptides were loaded on the RMA-S-HHD cells, and the ability of the selected G1 scFv Ab to bind to peptide-loaded cells was monitored by FACS.
Denkberg, G., Lev, A., Eisenbach, L., Benhar, I., & Reiter, Y. (2003). Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. Journal of immunology (Baltimore, Md. : 1950), 171(5), 2197–2207.
Figure 3 Immunohistochemical staining of melanoma cells with G1 scFv.
HLA-A2-positive or HLAA2-negative gp100-expressing melanoma cells or control MDA-MB231 breast carcinoma cells were stained in situ by G1 scFv, followed by detection with HRP-labeled antiMyc Ab.
Denkberg, G., Lev, A., Eisenbach, L., Benhar, I., & Reiter, Y. (2003). Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. Journal of immunology (Baltimore, Md. : 1950), 171(5), 2197–2207.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-13 | Recombinant Anti-human A*02 Antibody | WB, IHC, FuncS | IgG |
MHH-13 | Recombinant Human Anti-human A*02 Antibody | IF, FC, FuncS | IgG |
FAMAB-0156JF | Human Anti-HLA-A2 Recombinant Antibody (clone 3PB2) | WB, ELISA, IHC, FuncS | Human IgG |
FAMAB-0157JF | Human Anti-HLA-A2 Recombinant Antibody (clone 3PC4) | WB, FC | Human IgG |
FAMAB-0158JF | Human Anti-HLA-A2 Recombinant Antibody (clone 3PF12) | WB, FC, Inhib | Human IgG |
There are currently no Customer reviews or questions for FAMAB-0167YC. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.